Vinpocetine-Acry® (Vinpocetine-Akri®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceVinpocetine + Indapamide + Metoprolol + EnalaprilVinpocetine + Indapamide + Metoprolol + Enalapril
Similar drugsTo uncover
  • Vinpocetine-Acry®
    pills inwards 
    AKRIKHIN HFK, JSC     Russia
    • Dosage form: & nbsppills
    Composition:
    One tablet contains:
    active substance: vinpocetine in terms of 100% substance - 5 mg; Excipients: lactose (sugar milk), silicon dioxide colloid (aerosil), potato starch, magnesium stearate.
    Description:Tablets white or white with a yellowish tinge color, flat-cylindrical, with a facet, allowed "marbling".
    Pharmacotherapeutic group:Cerebral blood flow improver
    ATX: & nbsp

    C.07.F.B.02   Metoprolol in combination with other antihypertensive agents

    Pharmacodynamics:
    Vasodilator, improves brain metabolism, increasing the intake of glucose and oxygen by brain tissue.
    Increases the resistance of neurons to hypoxia; facilitates the transport of glucose to the brain through the blood-brain barrier; translates the process of decay of glucose into an energetically more economical aerobic pathway; selectively blocks calcium-dependent phosphodiesterase; increases the content of adenosine monophosphate (AMP), cyclic guanosine monophosphate (cGMP) and adenosine triphosphate (ATP) of the brain.
    Promotes an increase in the content of noradrenaline and serotonin in the brain tissues; has an antioxidant effect. Reduces platelet aggregation and increased blood viscosity; increases the deforming ability of erythrocytes and blocks the utilization of adenosine by red blood cells; helps to increase the return of oxygen in the erythrocytes. Increases cerebral blood flow. Does not have the effect of "stealing" and enhances blood supply, especially in ischemic areas of the brain.
    Pharmacokinetics:

    When ingested quickly absorbed. Time to reach the maximum concentration in blood plasma - 1 hour. Absorption occurs mainly in the proximal parts of the gastrointestinal tract. When passing through the wall of the intestine is not exposed to metabolism. The maximum concentration in the tissues is noted 2-4 hours after ingestion. Communication with proteins - 66%, bioavailability with ingestion - 7%. Clearance 66.7 l / h, exceeds the plasma volume of the liver (50 l / h), which indicates extrahepatic metabolism. At repeated receptions the kinetics has linear character. The half-life in humans is 4.83 ± 1.29 h.It is excreted by the kidneys and through the intestine in a ratio 3:2. Penetrates through the placental barrier.

    Indications:

    - reduction of neurological and psychiatric symptoms in various forms of cerebral circulatory insufficiency (including the reducing step ischemic or hemorrhagic stroke, the effects of stroke, transient ischemic attack, vascular dementia; vertebrobasilar insufficiency, cerebral atherosclerosis, traumatic and hypertensive encephalopathy);

    - Chronic vascular diseases of the choroid and retina;

    - Perceptual hearing loss, Meniere's disease, idiopathic tinnitus.

    Contraindications:

    - acute phase of hemorrhagic stroke, severe ischemic heart disease, severe arrhythmias, hypersensitivity to any of the components of the drug;

    - pregnancy (possibly placental bleeding and spontaneous abortion, probably as a result of increased placental blood supply);

    - lactation period (when using the drug, it is necessary to stop breastfeeding);

    - Children under 18 years (due to insufficient data).

    Dosing and Administration:

    Inside, after eating, 1 tablet 3 times a day. The initial daily dose is 15 mg. The maximum daily dose is 30 mg. Duration of treatment to 3 months. In diseases of the kidneys or liver, the drug is prescribed in the usual dose. Before cancellation, the dose should be gradually reduced.

    Side effects:

    From the side of the cardiovascular system: ECG change (segment depression ST, lengthening the interval QT), tachycardia, extrasystole, lability of blood pressure, sensation of hot flashes.

    From the central nervous system: sleep disturbances (insomnia or increased drowsiness), dizziness, headache.

    From the side of the digestive system: dry mouth, nausea, heartburn. .

    Other: allergic reactions, general weakness, increased sweating.

    Overdose:

    Symptoms: increased severity of side effects.

    Treatment: gastric lavage, reception of activated charcoal, symptomatic therapy.
    Interaction:

    Interactions are not observed with simultaneous use with β-blockers (chloranolol, pindolol), clopamid, glibenclamide, digoxin, acenocoumarol, hydrochlorothiazide, imipramine.

    The simultaneous use of vinpocetine and methyldopa sometimes caused some strengthening of the hypotensive effect, so this treatment requires regular monitoring of blood pressure.

    Despite the lack of data confirming the possibility of interaction, it is recommended to exercise caution when concurrently administering with the drugs central, antiarrhythmic and anticoagulant action.

    Increases the risk of hemorrhagic complications against heparin therapy.

    Special instructions:

    Presence of the syndrome of the prolonged interval QT and taking medications that cause lengthening of the interval QT, requires periodic ECG monitoring.

    Effect on the ability to drive transp. cf. and fur:Data on the effect of vinpocetine on the ability to drive a car and perform work that requires rapidity of psychomotor reactions, no.
    Form release / dosage:

    Tablets 5 mg.

    Packaging:

    For 10 tablets in a planar cell package.

    5 contour mesh packages together with instructions for use in a pack of cardboard.
    Storage conditions:

    List B. In a dry, the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    4 years.Do not use after the expiration date.

    Terms of leave from pharmacies:On prescription
    Registration number:P N002144 / 01
    Date of registration:15.12.2008 / 28.09.2016
    Expiration Date:Unlimited
    The owner of the registration certificate:AKRIKHIN HFK, JSC AKRIKHIN HFK, JSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp19.02.2017
    Illustrated instructions
      Instructions
      Up